Ashwagandha Adulteration Threatens US Supply Chain, Probiotics Drive China's Growth

London, United Kingdom — 17 January 2019

The US dietary supplement market for ashwagandha (Withania somnifera) is experiencing significant growth, with mainstream sales increasing by over 67% in 2017, according to the HerbalGram 2017 Herb Market Report. This escalating demand, coupled with its status as a top-selling Ayurvedic herb, has led to increased instances of economic adulteration within the supply chain. The Botanical Adulterants Prevention Program (a collaboration between the American Botanical Council, American Herbal Pharmacopoeia, and the National Center for Natural Products Research) has issued a bulletin detailing the addition of ashwagandha leaves and stems to root powders and extracts. This practice dilutes product efficacy and integrity, posing a substantial risk to brand reputation and consumer trust.

Concurrently, the Chinese supplement industry is undergoing a strategic transformation driven by probiotics and e-commerce. A Mintel report identifies probiotics as a top priority for Chinese consumers, valued for their digestive, immunity, and skin health benefits. This blurs the line between functional foods and health supplements, attracting traditional food and beverage manufacturers. Major players like By-Health and Amway are intensifying their focus on probiotics, fostering fierce competition. E-commerce platforms are critical for market penetration, with By-Health leveraging this channel to expand market share while direct selling firms reported subdued performance in 2018.

Regulatory scrutiny remains paramount, exemplified by the Australian Therapeutic Goods Administration (TGA) recalling Chinese herbal cough products. These products, specifically Beijing Tong Ren Tang's bronchi-cough pills and Qiguanyan Kesou Tanchuanwan, were found to contain prohibited substances such as aristolochic acid and amygdalin. The TGA advised immediate discontinuation and return of products, underscoring the severe consequences of non-compliance and the necessity for rigorous quality assurance on imported raw materials and finished goods.

What this means for United Kingdom

UK manufacturers sourcing ashwagandha for the growing adaptogen market must implement enhanced identity testing protocols to mitigate adulteration risks, preventing potential product recalls and brand damage. Compliance with FSA and MHRA guidelines on botanical sourcing and traceability is critical for consumer safety and market access. For brands targeting export to Asia, particularly China, understanding the dominance of e-commerce and the rising demand for probiotics is essential for market entry and competitive positioning. Reformulation and digital marketing strategies are key to capitalising on this shift, while maintaining stringent quality checks for all imported ingredients is non-negotiable.

Innovation in sports nutrition remains a critical differentiator in a crowded UK market. Bulk Powders' NPD supervisor, Jack Weekes, identifies veganism, cognitive health, and sustainability as key drivers for product development. Brands should consider these segments to create novel offerings and address evolving consumer preferences. Furthermore, the rise of AI-driven platforms like Spoon Guru, expanding into the US after UK success with Tesco, signals a growing demand for personalised nutrition solutions. UK brands should explore integration opportunities with such platforms to enhance product discoverability for consumers with specific dietary needs or preferences.

Many leading brands in this category are manufactured in partnership with Supplement Factory.